Progyny's leadership will speak at March investor conferences, discussing fertility technology and women's health initiatives.
Quiver AI Summary
Progyny, Inc. announced that its leadership team will participate in several investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum. CFO Mark Livingston will speak at the Leerink Partners conference on March 10, while CEO Pete Anevski will present at both the Barclays conference on March 11 and the KeyBanc Forum on March 17. COO Melissa Cummings will also join a panel on fertility technology and women’s health at the KeyBanc Forum. Live audiocasts of the events will be available on Progyny's investor relations website. Progyny, headquartered in New York City, is recognized for its leadership in women's health and family building solutions, providing comprehensive services that support patients and reduce healthcare costs.
Potential Positives
- Progyny's leadership team is actively engaging with investors at multiple prominent healthcare conferences, showcasing the company's commitment to transparency and investor relations.
- The participation of high-level executives in discussions and panels reflects the company's expertise and thought leadership in women's health and family building solutions.
- Progyny is consistently recognized for its impactful contributions to the healthcare sector, being listed among prestigious rankings such as TIME100 Most Influential Companies and CNBC Disruptor 50.
Potential Negatives
- The press release lacks specific information regarding the financial performance or projections for Progyny, which may raise concerns among investors about transparency and future growth potential.
- There is no mention of any recent challenges or developments in the competitive landscape, which could imply that the company is facing difficulties that it has chosen not to disclose.
- Highlighting participation in several conferences but not disclosing any new product launches or strategic initiatives may create skepticism about the company's current momentum in the market.
FAQ
What investor conferences will Progyny participate in March 2026?
Progyny will participate in the Leerink Partners Global Healthcare Conference, Barclays Global Healthcare Conference, and KeyBanc Capital Markets Healthcare Forum.
Who will represent Progyny at the Leerink Partners Global Healthcare Conference?
Mark Livingston, the Chief Financial Officer, will represent Progyny at the Leerink Partners Global Healthcare Conference.
When is the KeyBanc Capital Markets Healthcare Forum using Progyny's leadership?
The KeyBanc Capital Markets Healthcare Forum is on March 17, 2026, with participation from Melissa Cummings and Pete Anevski.
Where can I find the live audiocasts from the investor conferences?
Live audiocasts and replays will be available in the Events and Presentations section of Progyny's investor relations website.
What services does Progyny offer in women's health?
Progyny offers comprehensive family building solutions, including concierge support, education, access to specialists, and innovative digital tools.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PGNY Insider Trading Activity
$PGNY insiders have traded $PGNY stock on the open market 9 times in the past 6 months. Of those trades, 1 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $PGNY stock by insiders over the last 6 months:
- PETER ANEVSKI (CHIEF EXECUTIVE OFFICER) purchased 79,500 shares for an estimated $1,930,896
- MARK S. LIVINGSTON (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 21,975 shares for an estimated $560,362.
- ALLISON SWARTZ (EVP, GC) has made 0 purchases and 5 sales selling 9,784 shares for an estimated $196,473.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PGNY Revenue
$PGNY had revenues of $318.4M in Q4 2025. This is an increase of 6.69% from the same period in the prior year.
You can track PGNY financials on Quiver Quantitative's PGNY stock page.
$PGNY Hedge Fund Activity
We have seen 144 institutional investors add shares of $PGNY stock to their portfolio, and 194 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. removed 1,858,195 shares (-12.5%) from their portfolio in Q4 2025, for an estimated $47,718,447
- WELLINGTON MANAGEMENT GROUP LLP added 1,621,688 shares (+260.9%) to their portfolio in Q4 2025, for an estimated $41,644,947
- CITADEL ADVISORS LLC added 1,238,899 shares (+134.4%) to their portfolio in Q4 2025, for an estimated $31,814,926
- MARSHALL WACE, LLP removed 1,072,733 shares (-92.5%) from their portfolio in Q4 2025, for an estimated $27,547,783
- ALLIANZ ASSET MANAGEMENT GMBH added 841,365 shares (+4141.8%) to their portfolio in Q4 2025, for an estimated $21,606,253
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 836,652 shares (+inf%) to their portfolio in Q4 2025, for an estimated $21,485,223
- LOOMIS SAYLES & CO L P added 775,580 shares (+inf%) to their portfolio in Q4 2025, for an estimated $19,916,894
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PGNY Analyst Ratings
Wall Street analysts have issued reports on $PGNY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citizens issued a "Market Outperform" rating on 01/20/2026
To track analyst ratings and price targets for $PGNY, check out Quiver Quantitative's $PGNY forecast page.
$PGNY Price Targets
Multiple analysts have issued price targets for $PGNY recently. We have seen 7 analysts offer price targets for $PGNY in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- David Larsen from BTIG set a target price of $30.0 on 03/05/2026
- Jailendra Singh from Truist Securities set a target price of $28.0 on 03/02/2026
- Scott Schoenhaus from Keybanc set a target price of $28.0 on 03/02/2026
- Constantine Davides from Citizens set a target price of $30.0 on 01/20/2026
- Glen Santangelo from Barclays set a target price of $29.0 on 12/09/2025
- Richard Close from Canaccord Genuity set a target price of $26.0 on 11/17/2025
- Lisa Gill from JP Morgan set a target price of $26.0 on 11/11/2025
Full Release
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners Global Healthcare Conference, the Barclays Global Healthcare Conference, and the KeyBanc Capital Markets Healthcare Forum.
At the Leerink Partners Global Healthcare Conference, Mark Livingston, Chief Financial Officer, will participate in a fireside chat on March 10, 2026, at 10:40 a.m. Eastern Time.
At the Barclays Global Healthcare Conference, Pete Anevski, Chief Executive Officer, will participate in a fireside chat on March 11, 2026, at 1:00 p.m. Eastern Time.
At the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, Melissa Cummings, Chief Operating Officer, will participate in a panel discussion on fertility technology and women’s health at 12:00 p.m. Eastern Time, and Pete Anevski will participate in a fireside chat at 3:00 p.m. Eastern Time.
Live audiocasts and replays of the webcasted fireside sessions will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com .
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com .
For Further Information, Please Contact:
Investors:
James Hart
[email protected]
Media:
Alexis Ford
[email protected]
